Gustavo Viani, Professor at the Faculty of Medicine of Botucatu, São Paulo State University (UNESP), shared on LinkedIn:
“Can 20 Fractions Compete? A Game Changer in Cervical Cancer RT?
The HYPOCx-iRex Phase II RCT investigated a 44 Gy/20F regimen vs standard 45 Gy/25F in LACC. Here’s what they found
Objective
Compare safety and efficacy of hypofractionated chemoradiation vs conventional RT.
Methods
- n=40, open-label RCT
- IMRT + IGABT + cisplatin
- HYPO arm = 44Gy/20F
- CVRT arm = 45Gy/25F
Results
- OTT: ↓ 39 vs 47 days (P<0.001)
- GI Gr≥3: HYPO 43% vs CVRT 32%
- Para-aortic control at 24 mo: HYPO 100% vs 71% (P=0.003)
- HRQoL ↓ during RT, recovered after
Conclusion
- HYPO is feasible, efficient, and may enhance nodal control. Awaiting long-term data.”
More posts featuring Gustavo Viani.